Quinolone-based HDAC inhibitors

Abstract HDAC inhibitors emerged as promising drug candidates in combating wide variety of cancers. At present, two of the compounds SAHA and Romidepsin were approved by FDA for cutaneous T-cell lymphoma and many are in various clinical phases. A new quinolone cap structure was explored with hydroxamic acid as zinc-binding group (ZBG). The pan HDAC inhibitory and antiproliferative activities against three human cancer cell lines HCT-116 (colon), NCI-H460 (lung) and U251 (glioblastoma) of the compounds (4a–4w) were evaluated. Introduction of heterocyclic amines in CAP region increased the enzyme inhibitory and antiproliferative activities and few of the compounds tested are metabolically stable in both MLM and HLM.

[1]  P. Zinzani,et al.  Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Bradner,et al.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. , 2012, Blood.

[3]  G. Otterson,et al.  Romidepsin: a novel histone deacetylase inhibitor for cancer , 2011, Expert opinion on investigational drugs.

[4]  Kay Lin Goh,et al.  Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. , 2011, Journal of medicinal chemistry.

[5]  P. Marks.  The clinical development of histone deacetylase inhibitors as targeted anticancer drugs , 2010, Expert opinion on investigational drugs.

[6]  Robert A Copeland,et al.  Targeting epigenetic enzymes for drug discovery. , 2010, Current opinion in chemical biology.

[7]  Michelle R. Arkin,et al.  Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II , 2010, PloS one.

[8]  A. Kozikowski,et al.  Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents. , 2010, Journal of medicinal chemistry.

[9]  Delong Liu,et al.  Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents , 2010, Journal of hematology & oncology.

[10]  S. Chuncharunee,et al.  Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand , 2010, Journal of hematology & oncology.

[11]  S. Minucci,et al.  Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. , 2009, Cancer letters.

[12]  C. Marson,et al.  Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. , 2009, Anti-cancer agents in medicinal chemistry.

[13]  A. Kozikowski,et al.  Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. , 2009, Bioorganic & medicinal chemistry letters.

[14]  U. Hoch,et al.  Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models , 2009, Cancer Chemotherapy and Pharmacology.

[15]  Peter A. Jones,et al.  Chromatin, cancer and drug therapies. , 2008, Mutation research.

[16]  Q. You,et al.  Design, Synthesis and Antitumor Activity of 3-substituted Quinolone Derivatives (I) , 2008 .

[17]  R. Butler.  Non-invasive tests in animal models and humans: a new paradigm for assessing efficacy of biologics including prebiotics and probiotics. , 2008, Current pharmaceutical design.

[18]  Kyle V. Butler,et al.  Chemical origins of isoform selectivity in histone deacetylase inhibitors. , 2008, Current pharmaceutical design.

[19]  K. Glaser.  HDAC inhibitors: clinical update and mechanism-based potential. , 2007, Biochemical pharmacology.

[20]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[21]  H. Hess-Stumpp.  Histone deacetylase inhibitors and cancer: from cell biology to the clinic. , 2005, European journal of cell biology.

[22]  D. Wegener,et al.  Improved fluorogenic histone deacetylase assay for high-throughput-screening applications. , 2003, Analytical biochemistry.

[23]  A. Loupy,et al.  Microwave effects in solvent-free esters aminolysis , 2003 .

[24]  J. Li,et al.  Name Reactions: A Collection of Detailed Reaction Mechanisms , 2002 .

[25]  A. D. Rodrigues,et al.  Use of in vitro human metabolism studies in drug development. An industrial perspective. , 1994, Biochemical pharmacology.